volume 24, issue s2, P43-52 2011
DOI: 10.3233/jad-2011-110020
View full text
|
|
Share

Abstract: Alzheimer's disease (AD) continues to be one of most difficult human diseases to treat. The past 18 months have been a cruel reminder of the challenges of finding new and effective treatments. In 2010, several large Phase III clinical trials were terminated for lack of therapeutic efficacy. Concurrently, an NIH expert review panel was resigned to conclude that there was insufficient scientific evidence to recommend any treatment choices for slowing the progression of AD. Why has this disease proved so daunting…

Expand abstract